| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 47,638 | 45,379 | ||
| Accounts receivable due from spn - related party | 426 | 882 | ||
| Accounts receivable | 351 | - | ||
| Prepaid expenses and other current assets | 3,112 | 2,424 | ||
| Total current assets | 51,527 | 48,685 | ||
| Property and equipment, gross | 64,953 | - | ||
| Less accumulated depreciation and amortization | 56,375 | - | ||
| Property and equipment, net | 8,578 | 9,622 | ||
| Operating lease assets | 74,669 | 76,794 | ||
| Restricted cash | 8,668 | 8,668 | ||
| Other non-current assets | 31 | 31 | ||
| Total assets | 143,473 | 143,800 | ||
| Accounts payable | 1,677 | 2,200 | ||
| Accrued expenses and other current liabilities | 6,382 | 5,809 | ||
| Accrued liabilities due to spn - related party | 4,450 | 13,453 | ||
| Operating lease liabilities | 9,920 | 9,478 | ||
| Total current liabilities | 22,429 | 30,940 | ||
| Operating lease liabilities, net of current portion | 75,333 | 77,956 | ||
| Other long-term liabilities | 2,014 | 1,954 | ||
| Total liabilities | 99,776 | 110,850 | ||
| Common stock, 0.001 par value 360,000,000 shares authorized at september 30, 2025 and december 31, 2024 8,764,664 and 8,650,227 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 9 | 9 | ||
| Additional paid-in capital | 1,000,756 | 998,213 | ||
| Accumulated other comprehensive loss | 0 | 0 | ||
| Accumulated deficit | -957,068 | -965,272 | ||
| Total stockholders' equity | 43,697 | 32,950 | ||
| Total liabilities and stockholders' equity | 143,473 | 143,800 | ||
Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (MCRB)